Abstract
Objective:To analyze the effect of decitabine combined with conventional chemotherapy on myelodysplastic syndrome (MDS) and its influencing factors.Methods:Eighty patients with MDS who were admitted to our hospital were selected by this study between February 2017 and February 2018. The selected patients were divided into a traditional group (CAG/DA scheme) and the combined group (DAC combined with CAG/DA scheme) according to the random number table method, 40 each. The clinical treatment effects of the two groups were compared, and the influencing factors of the effect were analyzed.Results:After four courses of treatment, the difference in the total effective rate between the two groups were statistically significant (P<0.05); the difference in the incidence of adverse reactions and in the overall survival (OS) rate between the two groups were not statistically significant (P>0.05). However, the progression free survival (PFS) rate of the combined group was significantly higher compared with the traditional group (P<0.05); the Hb level, WHO stage and and karyotype of the patients before treatment had significant influence on the treatment effect (P<0.05).Conclusion:DAC in combination with conventional chemotherapy has good effect in the treatment of MDS, and it will not increase adverse reactions. In addition to treatment scheme, the influencing factors of the effect of treatment for MDS also include Hb, WHO stage and karyotype.
Highlights
Myelodysplastic syndrome (MDS) is a common disease in the blood system, which is mainly caused by the abnormal development of myeloid cells and ineffective hematopoiesis
The total effective rate of the combined group was 72.5%, which was significantly higher than that of the traditional group (40%) (P0.05, Table II)
The median overall survival (OS) was 18 [530] months, the median progression free survival (PFS) was 8 [3-25] months, and 10 patients transformed into acute myeloid leukemia
Summary
Myelodysplastic syndrome (MDS) is a common disease in the blood system, which is mainly caused by the abnormal development of myeloid cells and ineffective hematopoiesis. It is characterized by the increase of primordial cells and the increase and morphological abnormality of of bone marrow nucleated cells.. Decitabine is a specific DNA methyltransferase inhibitor, which can induce tumor cells to turn into normal cells or to die.. The clinical application time of decitabine in China is relatively short, and large sample data are not yet available to support whether factors such as Revised International Prognostic Scoring System (IPSS-R) risk stratification and genetic difference will affect the treatment effect of DAC for MDS. This study explored the effect of DAC combined with conventional chemotherapy on MDS and its influencing factors, in order to provide more optimal choices for clinical practice
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
